Key result
Rosuvastatin 20 mg daily decreased plasma ADMA levels significantly more than atorvastatin 40 mg daily in 83 patients with hypercholesterolemia and mild coronary artery stenosis.
Why the study?
Does rosuvastatin 20 mg reduce plasma ADMA levels more than atorvastatin 40 mg in patients with hypercholesterolemia and mild coronary artery stenosis?
RCT (n=83)
Does rosuvastatin 20 mg reduce plasma ADMA levels more than atorvastatin 40 mg in patients with hypercholesterolemia and mild coronary artery stenosis?
Rosuvastatin 20 mg daily reduces plasma ADMA levels significantly more than atorvastatin 40 mg daily, which may contribute to improved endothelial function in patients with hyperlipidemia and mild CAD.
Rosuvastatin may be preferred over atorvastatin for endothelial effects in hypercholesterolemia; extends head-to-head statin data to ADMA in mild CAD.
Elevated plasma levels of asymmetric dimethylarginine (ADMA) are prevalent in patients with hypercholesterolemia and coronary artery disease. A total of 83 patients with hypercholesterolemia and angiographically documented mild coronary artery stenosis were randomized to rosuvastatin treatment (20 mg) or atorvastatin treatment (40 mg) once daily for 6 weeks after a 4-week dietary lead-in phase. Both statins decreased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride levels effectively. Only rosuvastatin increased high-density lipoprotein cholesterol (HDL-C) levels. Both rosuvastatin and atorvastatin decreased plasma ADMA levels; rosuvastatin had a significantly greater effect. The reduction in ADMA levels were correlated with the reduction in TC and LDL-C levels as well as LDL-C-HDL-C ratio. Treatment with rosuvastatin or atorvastatin in patients with hyperlipidemia with mild coronary artery stenosis may lead to a decrease in ADMA levels, which may contribute to improved endothelial function.
No takes yet. Share an insight, caveat, or question.
Kurtoğlu et al. (2013) conducted an RCT in Hypercholesterolemia and mild coronary artery stenosis (n=83). Rosuvastatin vs. Atorvastatin 40 mg once daily was evaluated on Plasma levels of asymmetric dimethylarginine (ADMA). Rosuvastatin 20 mg daily decreased plasma ADMA levels significantly more than atorvastatin 40 mg daily in 83 patients with hypercholesterolemia and mild coronary artery stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: